Physician profile
Robert Knox
NPI 1457349425
$20,379.69
in general payments reported to CMS, 2019-2025
48 companies · $2,810 in 2025
The $2,810 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,891 · 2020: $2,256 · 2021: $2,665 · 2022: $3,004 · 2023: $4,639 · 2024: $3,115 · 2025: $2,810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,645 · Consulting Fee: $1,800 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,644.74 |
| Consulting Fee | $1,800.00 |
| Education | $118.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,260.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,707.23 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,858.80 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $1,258.35 | 2019-2025 | |
| Janssen Biotech, INC. | $1,192.17 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $864.95 | 2019-2025 | Sucraid |
| Pfizer INC. | $592.46 | 2019-2025 | |
| Lilly USA, LLC | $527.31 | 2023-2025 | Omvoh |
| Braintree Laboratories, INC. | $439.73 | 2019-2025 | Suflave, Sutab |
| Genzyme Corporation | $384.55 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $341.39 | 2019-2024 | Linzess |
| Madrigal Pharmaceuticals | $325.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $301.26 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $285.91 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $272.51 | 2022-2025 | Dupixent |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $261.85 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $249.71 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $209.15 | 2021-2023 | |
| Redhill Biopharma INC. | $207.76 | 2020-2023 | Talicia |
| Ardelyx, INC. | $163.94 | 2022-2025 | Ibsrela |
| Organon LLC | $142.84 | 2023-2025 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $140.95 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $138.47 | 2021-2024 | Ocaliva |
| Celltrion USA INC. | $137.25 | 2023-2025 | Vegzelma, Yuflyma |
| Phathom Pharmaceuticals, INC. | $126.69 | 2023-2025 | Voquezna |
| Amgen INC. | $119.42 | 2022-2025 | Avsola, Amjevita, Uplizna |
| Novo Nordisk INC | $107.18 | 2021-2025 | Wegovy |
| Aimmune Therapeutics, INC. | $86.32 | 2024-2025 | Zenpep |
| Alfasigma USA, INC. | $83.60 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $61.25 | 2022 | |
| Ucb, INC. | $60.23 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.22 | 2023-2024 | Cyltezo |
| Daiichi Sankyo INC. | $54.17 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $48.46 | 2024-2025 | Iqirvo |
| Allergan, INC. | $41.35 | 2019 | |
| Medtronic, INC. | $37.14 | 2021-2022 | |
| Shire North American Group INC | $31.00 | 2019 | |
| Capsovision, INC. | $27.59 | 2023-2024 | Capsocam Plus |
| Mylan Institutional INC. | $23.54 | 2023 | Hulio |
| Alnylam Pharmaceuticals INC. | $23.28 | 2025 | Givlaari |
| Exact Sciences Corporation | $22.26 | 2023 | Cologuard Collection Kit |
| Lucid Diagnostics INC. | $20.03 | 2023 | |
| Echosens North America, INC. | $16.49 | 2025 | Fibroscan |
| Shionogi INC | $15.11 | 2019 | |
| Evoke Pharma, INC. | $14.98 | 2025 | |
| Dynavax Technologies Corporation | $14.54 | 2022 | |
| Hologic Sales and Service, LLC | $11.63 | 2021 | |
| Endogastric Solutions, INC | $9.48 | 2023 | Esophyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.